# Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz

> **NCT05330273** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Ganaplacide
- **COMBINATION_PRODUCT:** Lumefantrine
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT05330273
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-28
- **Primary completion:** 2022-11-22
- **Final completion:** 2022-11-22
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05330273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05330273, "Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05330273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*